Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus
Shereen Oon, Molla Huq, Vera Golder, Pei Xuan Ong, Eric F Morand, Mandana Nikpour
ANNALS OF THE RHEUMATIC DISEASES | BMJ PUBLISHING GROUP | Published : 2019
Related Projects (1)
Awarded by National Health and Medical Research Council (NHMRC) Career Development Fellowship
MN is supported by a National Health and Medical Research Council (NHMRC) Career Development Fellowship (APP1126370). SO was supported by a postdoctoral fellowship from Arthritis Australia/Arthritis Victoria. Project funding was received from the St Vincent's Hospital Research Endowment Fund.